NFL BIOSCIENCES: co-development agreement for a drug candidate to reduce alcohol consumption
02 Februar 2022 - 5:45PM
NFL BIOSCIENCES: co-development agreement for a drug candidate to
reduce alcohol consumption
NFL Biosciences: co-development agreement for a drug candidate
to reduce alcohol consumption
Co-development agreement for NFL-301, a drug
candidate to reduce alcohol consumption, with plans to submit a
proof of concept clinical trial authorization application in the
United States in 2022
Unique natural positioning for NFL-301 on a
global multibillion-dollar market
NFL Biosciences SA, a biopharmaceutical
company that is developing botanical drugs for the
treatment of addictions, and ATHENA
Pharmaceutiques, a market leader for the
development and manufacturing of
oral delivery drugs, are
announcing that they have set up a co-development
agreement. ATHENA
Pharmaceutiques will
manage the development and manufacturing
of NFL-301, a natural drug candidate from NFL Biosciences
aimed at reducing alcohol consumption, while NFL Biosciences
will draw up and lead the
clinical program.
CO-DEVELOPMENT AGREEMENT FOR
NFL-301
The partnership between NFL Biosciences and
ATHENA Pharmaceutiques will involve developing NFL-301 at least
until its placebo-controlled efficacy has been demonstrated as a
treatment for reducing alcohol consumption. A proof of concept
clinical trial application could be submitted in 2022 in the United
States.
NFL Biosciences and ATHENA Pharmaceutiques will
make a joint investment and will share future revenues based on
their respective investments.
NFL-301’S UNIQUE, NATURAL POSITIONING ON
A MULTIBILLION-DOLLAR
MARKET
37 million Americans and 80 million Europeans
have excessive alcohol consumption at least once a week (sources:
Centers for Disease Control and Prevention and Institute of Alcohol
Studies). Alcohol is the leading risk factor for premature
mortality and disability among those aged 15 to 49 years,
accounting for 10 percent of all deaths in this age group (source:
WHO).
The reduction of alcohol consumption potentially
represents a multibillion-dollar market with unmet needs and
limited competition.
NFL-301 has a unique positioning because it is a
natural drug candidate and it aims to help people reduce their
alcohol consumption and particularly binge drinking episodes.
Bruno Lafont, Chief Operating Officer and
co-founder of NFL Biosciences: “We are delighted to set up this
co-development agreement with ATHENA Pharmaceutiques, which has
manufacturing sites in France and India. This agreement represents
the first step forward with our strategy aiming to rapidly bring a
second natural product to an advanced clinical phase in the
addiction treatment field. By targeting smoking cessation with
NFL-101 and the reduction of alcohol consumption with NFL-301, we
are positioning ourselves on the two addictive substances with the
most harmful effects worldwide and for which the current
therapeutic solutions are clearly insufficient. We are approaching
these two markets with innovative natural drug candidates based on
different active ingredients, reducing the risk for our
company”.
Alexandre Williams, President of Athena
Pharmaceutiques: “We were convinced by the clinical and commercial
potential of NFL-301, as well as by NFL Biosciences’ ability to
develop natural and innovative drug products. Through our financial
investment in this development program, we have chosen to actively
participate in the fight against excessive alcohol
consumption”.
About
NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in Montpellier which develops botanical drug candidates for
the treatment of addictions. NFL Bioscience's ambition is to bring
new, natural, safer and more effective therapeutic solutions to the
entire world population, including low- and middle-income
countries. Its most advanced product, called NFL-101, is a
standardized, nicotine-free tobacco leaf extract protected by two
patent families. NFL Biosciences intends to offer smokers who want
to quit a natural, safe, easy-to-administer and personalized
alternative. NFL Biosciences is also developing NFL-301, a natural
drug candidate for the reduction of alcohol consumption and has a
drug development project for the treatment of cannabis use
disorders.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contact
Bruno Lafont – info@nflbiosciences.com - +33 4
11 93 76 67
Agence Calyptus – nflbiosciences@calyptus.net -
+33 1 53 65 68 68
- 20220201_PR_NFLBiosciences_Athena_EN
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024